Pumitamig plus ifinatamab deruxtecan shows encouraging early activity in small cell lung cancer
The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase Ib/II BNT324-01 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung…
An investigational drug combination, pumitamig paired with elfetabart drozuntecan, showed promising initial results in treating small cell lung cancer (SCLC), according to early data presented at the 2026 World Conference on Lung Cancer. The combo consists of an investigational PD-L1 x VEGF-A bispecific antibody and a B7H3 antibody-drug conjugate. The FDA has not reviewed or approved any aspects of this report.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
